Yerem Yeghiazarians, MD
Interventional Cardiology · San Francisco, CANPI 1265477988
Payments from drug & device makers
Across 106 payments — averaging $55.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$4K
- Boston Scientific$937
- Shockwave Medical, Inc$183
- Cardiovascular Systems Inc.$105
- Abbott$77
- Teleflex LLC$24
- plus $36 from 2 others
What the payments were for
- Consulting fees$4,22572%
- Food & beverage$1,47425%
- Education$1342%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $4,472 |
| Boston Scientific | 75 | $937 |
| Shockwave Medical, Inc | 6 | $183 |
| Cardiovascular Systems Inc. | 14 | $105 |
| Abbott | 3 | $77 |
| Teleflex LLC | 1 | $24 |
| Amgen | 1 | $19 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$4,359
How this compares
$5,833 in reported general payments places this provider in the 35th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 24 | $32,679 |
| EliquisApixaban | 13 | $20,867 |
| Praluent PenAlirocumab | 12 | $8,768 |
| Ezetimibe | 60 | $2,531 |
| Atorvastatin Calcium | 67 | $907 |
| Metoprolol Succinate | 52 | $903 |
| ClopidogrelClopidogrel Bisulfate | 63 | $834 |
| Rosuvastatin Calcium | 30 | $516 |
| Amlodipine Besylate | 25 | $263 |
| Valsartan | 13 | $240 |
| Lisinopril | 20 | $156 |
| Losartan Potassium | 15 | $108 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in San Francisco
- Sammy ElmariahSan Francisco$4.2M
- Jacob MishellSan Francisco$1.7M
- Kendrick ShunkSan Francisco$1.2M
- Chun LinSan Francisco$1M
- Yousif AhmadSan Francisco$380K
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.